Strong Diagnostics, Biosimilar Pain Expected In Roche Q1
Good New Medicine Sales Should Also Feature In Results
Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.
